French Life Sciences Stock News

Teleperformance (ENXTPA:TEP) has reported its FY 2025 results with first half revenue of €5.1b and basic EPS of €4.22, while trailing twelve month figures show revenue of about €10.2b and EPS of €8.47. This gives investors a clear view of the group’s recent earnings power. Over recent periods the company has reported revenue of €5.08b and EPS of €4.85 in the first half of 2024, followed by revenue of €5.20b and EPS of €3.90 in the second half of 2024, before arriving at the latest half year...

AXA (ENXTPA:CS) reported strong full year 2025 earnings growth. The company announced the start of an annual share buyback program, subject to shareholder approval. Management reiterated confidence in AXA's existing plan for the business alongside these capital actions. For investors watching AXA at a share price of €41.46, the combination of solid earnings in 2025 and a proposed recurring buyback program puts fresh attention on the insurer's capital allocation choices. The stock has...

Market reports highlight accelerating growth in private aviation linked to technology and sustainability trends. Dassault Aviation société anonyme, listed as ENXTPA:AM, is referenced as a key player in business jets and advanced aircraft. New opportunities include electric and hybrid aircraft concepts and an expanding luxury travel ecosystem. Dassault Aviation société anonyme, through its Falcon business jets and defense activities, sits at the center of a private aircraft sector that is...

The Human Animal Bond Research Institute (HABRI) recently announced a new partnership with Virbac to advance science-based education and outreach on the health benefits of the human-animal bond for pets and people. This collaboration ties Virbac’s animal health expertise to growing scientific evidence that pet ownership supports physical function, mobility and overall well-being in humans. We’ll now examine how this HABRI partnership, with its emphasis on science-backed education around the...

Sopra Steria Group (ENXTPA:SOP) is back in focus after reporting an 18.3% rise in 2025 net profit, a return to organic revenue growth in Q4, and proposing a higher €5.30 per share dividend. See our latest analysis for Sopra Steria Group. The 1-day share price return of 1.16% and 7-day gain of 8.16% have come after management approved the 2025 results, announced the planned €5.30 dividend, and outlined further expansion in defence, aeronautics, public sector and AI. However, the year to date...

Technip Energies (ENXTPA:TE) has wrapped up FY 2025 with fourth quarter revenue of €1.8b and basic EPS of €0.48, capping a twelve month stretch where trailing revenue came in at €7.2b and basic EPS at €2.04. The company has seen quarterly revenue move between €1.74b and €1.94b since late 2024, while basic EPS has ranged from €0.47 to €0.70 over the same period, giving investors a clear view of how top line scale and per share earnings have tracked through the year. With net profit margins...

If you are wondering whether Amundi is priced attractively today, this article walks through what the current share price might be implying about its underlying value. With the stock at €81.05 and returns of 2.2% over 7 days, 8.6% over 30 days, 13.8% year to date, 25.0% over 1 year, 55.5% over 3 years and 70.3% over 5 years, many investors are asking whether the recent performance still leaves room for a reasonable entry point. Recent news around Amundi has kept attention on how large asset...

If you are wondering whether Kering is attractively priced right now, this article will walk through what the current share price might be implying about its value. The stock recently closed at €285.90, with returns of 2.8% over the last 7 days and 7.4% over the last 30 days. The year to date return stands at a 6.1% decline and the 1 year return at 8.2%, after a 45.7% decline over 3 years and a 39.5% decline over 5 years. These moves sit against ongoing discussion around how luxury spending...

Klépierre (ENXTPA:LI) has drawn fresh interest after reporting full year 2025 earnings and proposing a higher cash dividend, alongside several supervisory board changes that reshape the company’s governance backdrop. See our latest analysis for Klépierre. Those full year 2025 results and the 3% higher proposed dividend appear to sit behind recent share price momentum, with a 9.0% 1 month share price return and a 23.0% 1 year total shareholder return pointing to building confidence rather than...

Veolia Environnement (ENXTPA:VIE) FY 2025 Results Snapshot Veolia Environnement (ENXTPA:VIE) has reported FY 2025 first half revenue of €22.0b and basic EPS of €0.91, with trailing 12 month EPS of €1.70 on revenue of €44.4b framing the latest set of numbers. The company has seen revenue move from €44.7b to €44.4b on a trailing 12 month basis, while EPS has shifted from €1.47 to €1.70 over the same window. This sets up the current release against an 11.2% earnings growth profile and a net...

Schneider Electric (ENXTPA:SU) has released its FY 2025 numbers, reporting second half revenue of €20.8b and basic EPS of €3.99, alongside trailing 12 month revenue of €40.2b and EPS of €7.41. These figures frame the latest results against a fuller year of performance. The company’s revenue increased from €19.98b in the second half of 2024 to €20.8b in the second half of 2025, while basic EPS moved from €4.25 to €3.99 over the same periods. This sets up a results season in which investors are...

Quotient Sciences partnership extension and rare disease focus Ipsen (ENXTPA:IPN) is back in focus after extending its commercial supply partnership with Quotient Sciences to manufacture therapy for Fibrodysplasia Ossificans Progressiva, an ultra rare condition with highly specific treatment needs. The move includes Ipsen funding new equipment at Quotient Sciences' Boothwyn facility, aimed at handling highly potent compounds such as Sohonos and supporting commercial scale supply of multiple...

Getlink (ENXTPA:GET) has reported its FY 2025 results with second half revenue of €906 million and net income of €207 million, while the first half delivered €744 million of revenue and €113 million of net income, setting a clear earnings rhythm for the year. The company has seen half year revenue move from €806 million in the second half of 2024 to €906 million in the second half of 2025, alongside basic EPS of €0.26 in 2024 H2 and €0.21 in 2025 H1, giving investors a clear view of how top...

SEB (ENXTPA:SK) has wrapped up FY 2025 with second half revenue of €4.4b and basic EPS of €8.28, putting fresh numbers behind a year that also saw trailing twelve month revenue of €8.2b and EPS of €4.47. Over the past few periods, the group has seen revenue move from €4.5b in H2 2024 to €3.7b in H1 2025 and then €4.4b in H2 2025. Basic EPS shifted from €2.41 in H2 2024 to effectively flat at €0.01 in H1 2025 before rebounding to €8.28 in the latest half, leaving investors to weigh a low 1.6%...

Capgemini (ENXTPA:CAP) has just signed new deals with Deutsche Telekom and TELUS to advance network automation, alongside a partnership with OpenAI, which puts telecom and AI execution at the center of the stock story. See our latest analysis for Capgemini. Despite the fresh telecom and AI agreements, Capgemini’s recent share price performance has been weak, with a 30 day share price return of 18.67% and a year to date share price return decline of 24.01%. This has contributed to a 1 year...

Carrefour (ENXTPA:CA) posts FY 2025 results with weak first half but steadier trailing earnings picture Carrefour (ENXTPA:CA) has reported its FY 2025 numbers with a soft first half, booking €42.7b in revenue and a basic EPS loss of €0.56, while trailing twelve month figures point to revenue of €83.8b and EPS of €1.43. The company has seen first half revenue move from €41.4b with EPS of €0.04 in 2024 to €42.7b with an EPS loss in 2025, against a backdrop of trailing net profit margin sitting...

Publicis Groupe (ENXTPA:PUB) has moved to deepen its presence in retail media, with Publicis Media Middle East becoming the exclusive pilot agency partner for GoWit’s AI-driven GoWit One platform across the MENA region. See our latest analysis for Publicis Groupe. While the GoWit retail media deal, recent share repurchases and leadership changes in its media buying operations point to an active period for Publicis Groupe, the share price at €75.42 reflects a 30 day share price return of...

Compagnie de Saint-Gobain (ENXTPA:SGO) has drawn investor attention after recent share moves, with the stock showing mixed returns over the past week, month and past 3 months, prompting a closer look at its fundamentals. See our latest analysis for Compagnie de Saint-Gobain. At a share price of €86.86, Compagnie de Saint-Gobain’s recent 1-day and 7-day share price declines sit against a modest 30-day share price gain of 2.62%. Its 1-year total shareholder return decline of 6.44% contrasts...

Sanofi (ENXTPA:SAN) has received US FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis (AFRS) in adults and children. The European Medicines Agency has issued a positive opinion for Acoziborole Winthrop, developed with DNDi, as a treatment for sleeping sickness. Sanofi plans to donate Acoziborole Winthrop to the World Health Organization for use in tackling this rare and neglected tropical disease. For you as an investor, these milestones highlight how...

Arkema (ENXTPA:AKE) has come into focus after releasing full year 2025 results, showing sales of €9,068 million and net income of €63 million, alongside an annual dividend announcement of €3.60 per share. See our latest analysis for Arkema. Arkema’s latest results and dividend decision come after a sharp 21.20% 1 month share price return to €61.45 and a 17.38% year to date share price gain. However, the 1 year total shareholder return of 18.76% and 5 year total shareholder return of 23.27%...

Vallourec (ENXTPA:VK) has drawn fresh attention after signing a Memorandum of Understanding with Baker Hughes, focused on integrating its Delphy underground hydrogen storage solution with Baker Hughes compression technology for green hydrogen projects. See our latest analysis for Vallourec. The recent hydrogen storage MOU sits alongside other developments, including a share buyback program and board changes involving ArcelorMittal representation. This comes during a period where Vallourec’s...

The UK's Commission on Human Medicines has issued updated recommendations on the prescribing information for Valneva's chikungunya vaccine, IXCHIQ. The changes refine restrictions on use in specific patient groups following earlier concerns about adverse events. The update affects how IXCHIQ can be used in the UK and reflects ongoing post marketing safety monitoring. For investors watching Valneva (ENXTPA:VLA), this regulatory update lands at a time when the shares trade around €4.69. The...

TotalEnergies (ENXTPA:TTE) has signed a preliminary 20 year LNG offtake agreement linked to the proposed Alaska LNG project. The company plans to purchase 2 million tons of LNG per year, with volumes targeted for customers in Asian markets. The arrangement is tied to a direct Pacific shipping route that aims to shorten transit times from Alaska to Asia. TotalEnergies is already active across the LNG value chain. This new agreement would add a North American source to its mix if the project...

Exosens (ENXTPA:EXENS) is back in the spotlight after reporting 2025 sales of €468.2 million and net income of €42.7 million, alongside new 2026 revenue guidance and a proposed €0.30 per share dividend. See our latest analysis for Exosens. The latest earnings beat, new 2026 revenue guidance and the proposed €0.30 dividend appear to be feeding into strong momentum, with a 30 day share price return of 15.99% and a 1 year total shareholder return of 151.14% at a €62.4 share price. If this kind...